Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hypofraktioneret strålebehandling med hele bækkenet (WPRT) vs konventionelt fraktioneret WPRT ved prostatakræft (HOPE)

Er hypofraktioneret helbækkenstrålebehandling (WPRT) lige så godt tolereret som konventionelt fraktioneret WPRT hos patienter med prostatakræft? (HOPE-Trial)

The purpose of this research study is to determine if 5 (five) fractions of external radiotherapy with higher radiation doses per fraction to the pelvis leads to similar results to the standard of care external radiotherapy treatment that is comprised of 25 fractions of external radiotherapy with lower radiation doses per fraction to the pelvis.

This study aims to investigate the impact in quality of life associated with hypofractionated Whole Pelvis Radiotherapy (WPRT) in comparison to conventionally-fractionated WPRT in patients with unfavorable-intermediate and high-risk prostate cancers. This information is valuable as hypofractionated WPRT is a more attractive and convenient treatment approach, and may become the new standard of care if proven to be well-tolerated and effective. Therefore, this study aims to provide a more rational justification for use of hypofractionated WPRT in future larger randomized trials by comparing this strategy with the current standard of care. This study will also provide an initial understanding of the toxicity profile and cancer control associated with hypofractionated WPRT and High Dose Rate Brachytherapy (HDR-BT).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

58

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2N 4N2
        • Tom Baker Cancer Centre
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • BC Cancer
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • London Regional Cancer Program of the Lawson Health Research Institute

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  • Age 18 or older
  • Study Informed Consent provided
  • Pathologically proven diagnosis of prostatic adenocarcinoma
  • Unfavorable intermediate risk [with greater than 15% chance of node involvement based on Memorial Sloan Kettering Cancer Center (MSKCC) nomogram https://www.mskcc.org/nomograms/prostate] or high or very-high-risk prostate cancer based on National Comprehensive Cancer Network (NCCN) classification [Prostatic Specific Antigen (PSA) > 20 ng/mL or clinical cT3a or cT3b or Gleason 8-10]
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • No prior history of pelvic irradiation, brachytherapy, cryosurgery, High-Intensity Focused Ultrasound (HIFU), Transurethral Resection of the Prostate (TURP) or radical prostatectomy

Exclusion Criteria:

  • Presence of nodal or distant metastasis, as confirmed by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) of the chest/abdomen/pelvis and bone scan within 45 days of randomization
  • Plan for adjuvant docetaxel post-radiotherapy
  • Serious medical comorbidities or other contraindications to HDR-BT
  • Presence of inflammatory bowel disease
  • Presence of connective tissue disease
  • Medically unfit for general anesthesia
  • Unable or unwilling to complete questionnaires

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Conventionally-fractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Total dose: 45 Gy in 25 fractions WPRT

Eksperimentel: Hypofractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Total dose: 25 Gy in 5 fractions WPRT

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quality of Life (QOL) - late bowel function as measured by the EPIC questionnaire
Tidsramme: I year post treatment (approximately 3 years and 2 months)

Late bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quality of Life - acute urinary and sexual QOL as measured by the EPIC questionnaire
Tidsramme: 6 weeks post treatment (approximately 2 years and 3 months)

Acute urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) urinary and sexual domains. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

6 weeks post treatment (approximately 2 years and 3 months)
Quality of Life - acute bowel toxicity as measured by the EPIC questionnaire
Tidsramme: 6 weeks post treatment (approximately 2 years and 3 months)

Acute bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) approximately 6 weeks after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

6 weeks post treatment (approximately 2 years and 3 months)
Quality of Life - late bowel bother as measured by the EPIC questionnaire
Tidsramme: I year post treatment (approximately 3 years and 2 months)

Late bowel bother as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)
Quality of Life - late urinary and sexual QOL as measured by the EPIC questionnaire
Tidsramme: I year post treatment (approximately 3 years and 2 months)

Late urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC). The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)
International Prostate Symptom Score (IPSS)
Tidsramme: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

International Prostate Symptom Score (IPSS) as reported by the patient at 6 weeks, 1 year, and 2 years post treatment. The IPSS is a tool used for monitoring symptoms of prostate enlargement (benign prostatic hyperplasia). There are 7 questions related to urinary function. Responses are on a scale from 0 (best) to 5 (worst). Responses are added to come up with a total score, measuring if the patient is mildly symptomatic, moderately symptomatic, or severely symptomatic. There is 1 quality of life question related to urinary symptoms. Responses are on a scale from 0 (best) to 6 (worst).

6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
Toxicity - urinary, bowel, and sexual as measured by CTCAE version 4.0
Tidsramme: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

Urinary, bowel, and sexual toxicity will be measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4, at 6 weeks, 1 year, and 2 years post treatment.

6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
Prostatic Specific Antigen (PSA) curve
Tidsramme: 4 years post treatment (approximately 6 years and 2 months)

PSA curve at 4 years post-treatment.

4 years post treatment (approximately 6 years and 2 months)
Prostatic Specific Antigen (PSA) Nadir
Tidsramme: 4 years post treatment (approximately 6 years and 2 months)

PSA nadir at 4 years post-treatment.

4 years post treatment (approximately 6 years and 2 months)
Cost Effectiveness of Hypofractionated WPRT
Tidsramme: End of study (approximately 7 years and 2 months)

Cost effectiveness analysis of the hypofractionated arm in comparison to the conventionally fractionated treatment arm.

End of study (approximately 7 years and 2 months)
Overall Survival
Tidsramme: End of study (approximately 7 years and 2 months)

The time from randomization to death from any cause.

End of study (approximately 7 years and 2 months)
Biochemical Failure-Free Survival
Tidsramme: End of study (approximately 7 years and 2 months)

The time from randomization to biochemical failure (based on the Phoenix definition) or death from any cause, whichever occurs first.

End of study (approximately 7 years and 2 months)
Freedom from Local Failure
Tidsramme: End of study (approximately 7 years and 2 months)

The time from randomization to first local failure.

End of study (approximately 7 years and 2 months)
Freedom from Regional Failure
Tidsramme: End of study (approximately 7 years and 2 months)

The time from randomization to first regional failure.

End of study (approximately 7 years and 2 months)
Androgen Deprivation Therapy Free Survival
Tidsramme: End of study (approximately 7 years and 2 months)

The time from randomization to start of salvage ADT, death or last follow-up.

End of study (approximately 7 years and 2 months)
Metastasis Free Survival
Tidsramme: End of study (approximately 7 years and 2 months)

The time from randomization to development of metastasis, death or last follow-up.

End of study (approximately 7 years and 2 months)
Prostate Cancer Free Survival
Tidsramme: End of study (approximately 7 years and 2 months)

The time from randomization to death attributed to prostate cancer.

End of study (approximately 7 years and 2 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Lucas C Mendez, MD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. februar 2020

Primær færdiggørelse (Anslået)

1. september 2027

Studieafslutning (Anslået)

1. marts 2028

Datoer for studieregistrering

Først indsendt

6. december 2019

Først indsendt, der opfyldte QC-kriterier

11. december 2019

Først opslået (Faktiske)

12. december 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner